Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia

Hospital Universitario Dr. Jose E. Gonzalez

Status: Completed

Conditions: Acute Lymphoblastic Leukemia

Study type: Observational

Funder types: Other

Identifiers

NCT01380587

XCL1 in ALL

Details and patient eligibility

About

The purpose of the study is to determine the utility of XCL1 in the prognosis of acute lymphoblastic leukemia.

Full description

Each year approximately 256,000 children and adults around the world develop a form of leukemia, and 209,000 died from it. Recently, some studies have evaluated the relationship between the concentration of some cytokines and prognosis of acute lymphoblastic leukemia. XCL1 is a lymphotactin that belongs to a cytokine subfamily called C or γ with only one cysteine in the N-terminal residue. It has been found with significant expression of receptor mRNA XCL1 (XCR1) in T and B lymphocytes and related to hematological neoplasms. For these reasons, XCL1 could be a efficient marker of prognosis in patients with acute lymphoblastic leukemia.

Enrollment: 25 patients

Sex: All

Ages: 1+ year old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients with newly diagnosed acute lymphoblastic leukemia .

Exclusion criteria

• Patients with prior treatment with chemotherapeutic agents.
• Patients treated with immunosuppressants.
• Patients under 12 months old.
• Patients with a diagnosis or history of autoimmune diseases.
• Patients with a diagnosis or history of immunosuppressive diseases.
• Patients who do not agree to sign a Letter of Informed Consent.

Trial design

25 participants in 1 patient group

Acute Lymphoblastic Leukemia

Description:

We will invite patients with newly diagnosed acute lymphoblastic leukemia in the Department of Hematology, who had not received anticancer therapy and regardless the subtype and immunophenotype of the disease.